Analysts Set Axonics, Inc. (NASDAQ:AXNX) PT at $71.00

Shares of Axonics, Inc. (NASDAQ:AXNX) have received an average recommendation of “Hold” from the eight ratings firms that are covering the stock, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold rating. The average 12-month price objective among brokers that have covered the stock in the last year is $71.00.

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research note on Friday, November 8th.

Insider Activity at Axonics

In related news, CFO Kari Leigh Keese sold 2,961 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total transaction of $205,523.01. Following the transaction, the chief financial officer now owns 40,362 shares in the company, valued at $2,801,526.42. The trade was a 6.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.85% of the stock is owned by corporate insiders.

Institutional Trading of Axonics

Several institutional investors and hedge funds have recently bought and sold shares of AXNX. Headlands Technologies LLC grew its holdings in shares of Axonics by 31.1% during the 1st quarter. Headlands Technologies LLC now owns 1,117 shares of the company’s stock worth $77,000 after acquiring an additional 265 shares during the period. Murchinson Ltd. bought a new stake in shares of Axonics during the third quarter valued at approximately $209,000. Janney Montgomery Scott LLC purchased a new stake in Axonics in the first quarter worth $218,000. Xponance Inc. raised its holdings in Axonics by 7.5% in the second quarter. Xponance Inc. now owns 3,231 shares of the company’s stock worth $217,000 after purchasing an additional 225 shares in the last quarter. Finally, MML Investors Services LLC lifted its position in Axonics by 14.8% during the third quarter. MML Investors Services LLC now owns 4,107 shares of the company’s stock valued at $286,000 after buying an additional 529 shares during the period. 99.48% of the stock is currently owned by hedge funds and other institutional investors.

Axonics Price Performance

Shares of Axonics stock opened at $70.98 on Friday. Axonics has a one year low of $55.09 and a one year high of $71.05. The business’s 50 day simple moving average is $69.87 and its two-hundred day simple moving average is $68.60. The stock has a market capitalization of $3.63 billion, a P/E ratio of -591.45 and a beta of 0.82.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.